TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional presentations will be shared on Wednesday April 17, 2024.

Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated “The ULTIMATE I & II Phase 3 trials demonstrated robust clinical activity for BRIUMVI compared to teriflunomide and these post-hoc analyses provide interesting new insights and support BRIUMVI’s utility as an important treatment option for patients with relapsing forms of multiple sclerosis. We look forward to presenting two additional data sets this week during the AAN annual meeting.”

Link to Poster Presentation: MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbactions in the ULTIMATE I and II Trials Comparing Ublituximab vs. Teriflunomide

• Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
  

UPCOMING PRESENTATIONS AT AAN 2024:
Poster Presentation Title: Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies

• Presentation Date/Time: Wednesday, April 17, from 8:00 AM - 9:00 AM MST
• Session: P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2
• Abstract Number/Poster Number: 6023/017 in Neighborhood 6
• Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida

Poster Presentation Title: Earlier Initiation of Ublituximab Treatment Is Associated with Improved Disability Outcomes Among Treatment Naïve Participants in ULTIMATE I and II

• Presentation Date/Time: Wednesday, April 17, from 8:00 AM - 9:00 AM MST
• Session: P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2
• Abstract Number/Poster Number: 6400/001 in Neighborhood 6
• Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida

Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.